Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 10/20 | 0.64 |
| ▸ | VIPR1 | P32241 | 7/20 | 0.64 |
| ▸ | GLP1R | P43220 | 3/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.60 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.59 |
| ▸ | TFPI | P10646 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histatin 5 SCHEMBL29354282 | 0.93 | VIPR1 (0.61) | VIPR2VIPR1GLP1RECE1MUS81 | |
| Histatin 3 SCHEMBL29445556 | 0.90 | VIPR1 (0.69) | VIPR2VIPR1GLP1RECE1MUS81 | |
| SCHEMBL29581965 | 0.90 | VIPR1 (0.55) | VIPR2VIPR1GLP1RECE1MUS81 | |
| SCHEMBL30712750 | 0.86 | VIPR2 (0.62) | VIPR2VIPR1GLP1R | |
| SCHEMBL29623290 | 0.86 | VIPR2 (0.65) | VIPR2VIPR1GLP1RECE1MUS81 | |
| SCHEMBL29777861 | 0.85 | TFPI (0.62) | VIPR2VIPR1TFPI | |
| SCHEMBL30900782 | 0.84 | TFPI (0.65) | TFPI | |
| SCHEMBL30900790 | 0.84 | TFPI (0.65) | TFPI | |
| SCHEMBL29366809 | 0.84 | OPRL1 (0.55) | — | |
| SCHEMBL31211751 | 0.83 | TFPI (0.61) | VIPR2VIPR1GLP1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129271-A1 | LIPID DELIVERY VEHICLE | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-06-26 | — | — | WO | claimed |
| US-20240074970-A1 | COMPOSITIONS FOR THE DELIVERY OF PROTEINS | AFYX THERAPEUTICS A/S (DK) | 2024-03-07 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12618031-B2 | Delivery devices | THE METHODIST HOSPITAL SYSTEM (US) | 2026-05-05 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260041746-A1 | TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR VACCINATION | GEG TECH (FR) | 2026-02-12 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-11440881-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| WO-2022117764-A1 | FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF | INSTITUT CURIE (FR) | 2022-06-09 | — | — | WO | disclosed |
| US-11311610-B2 | Immune-modulating agents and uses therefor | UNIVERSITY OF TECHNOLOGY SYDNEY (AU) | 2022-04-26 | — | — | US | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440881-B2 | Thiosemicarbazates and uses thereof | TST, ABAT, AADAC | VIPR2 3336/4885VIPR1 3132/4885GLP1R 557/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | VIPR2 687/4885VIPR1 889/4885GLP1R 319/4885 |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | VIPR2 329/4885VIPR1 502/4885GLP1R 82/4885 |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | VIPR2 580/4885VIPR1 949/4885GLP1R 1837/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | VIPR2 153/4885VIPR1 321/4885GLP1R 3/4885 |
| US-12618031-B2 | Delivery devices | VEGFA, PGF, CD47 | VIPR2 750/4885VIPR1 696/4885GLP1R 337/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | VIPR2 684/4885VIPR1 574/4885GLP1R 116/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | VIPR2 501/4885VIPR1 751/4885GLP1R 1950/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | VIPR2 2776/4885VIPR1 2088/4885GLP1R 139/4885 |
| US-20260041746-A1 | TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR VACCINATION | RNMT, NSUN2, NSUN3 | VIPR2 4690/4885VIPR1 4611/4885GLP1R 4585/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | VIPR2 2819/4885VIPR1 1955/4885GLP1R 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.